CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
rapamune, mycophenolate mofetil and steroid +1 moredrug
Likely dose
rapamune, mycophenolate mofetil and steroid 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01005706
NCT01005706N/ACompleted

A Pilot Study Comparing Two Different Sirolimus-based Transition Regimens in African-American Renal Transplant Recipients

Medical University of South Carolina·interventional·Posted Nov 2, 2009·Updated Mar 11, 2016

In Brief

A clinical study evaluating rapamune, mycophenolate mofetil and steroid and tacrolimus, sirolimus and steroid for Absence; Kidney. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study's focus is to compare the level effectiveness and safety of regimens involving Sirolimus, Cellcept and steroid to Prograf, Sirolimus and steroid in African-American recipients of kidney transplants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAbsence; Kidney
CountriesUnited States

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2, 2009
Enrollment StartAug 1, 2009
Primary CompletionJul 1, 2013
Study CompletionJul 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 16.7 years ago

Interventions

rapamune, mycophenolate mofetil and steroiddrug

At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml. Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator.

tacrolimus, sirolimus and steroiddrug

Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml. At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.